Chemours (NYSE: CC) insider transactions
In the twelve months to 10 November 2026, executives and directors of Chemours reported 0 open-market sales and 7 open-market purchases of 31,537 shares ($488,649), by 7 people, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 12 August 2026 | Familiar Calderon Gerardo | See Remarks | Open-market purchase | +1,935 | $15.53 | 58,547 | Form 4 |
| 12 August 2026 | Will David | Chief Accounting Officer | Shares withheld for tax | −2,426 | $15.24 | 30,868 | Form 4 |
| 11 August 2026 | Dignam Denise | Chief Executive Officer | Open-market purchase | +3,378 | $14.95 | 339,916 | Form 4 |
| 7 August 2026 | Cranston Mary B | Director | Open-market purchase | +6,000 | $15.83 | 113,141 | Form 4 |
| 7 August 2026 | Martinko Joseph T. | See Remarks | Open-market purchase | +1,940 | $15.47 | 55,431 | Form 4 |
| 7 August 2026 | Foley Michael Robert | See Remarks | Open-market purchase | +1,934 | $15.51 | — | Form 4 |
| 7 August 2026 | Cowan Alister | Director | Open-market purchase | +13,000 | $15.62 | 56,988 | Form 4 |
| 6 August 2026 | Hostetter Shane | Chief Financial Officer | Shares withheld for tax | −3,087 | $15.11 | 99,348 | Form 4 |
| 6 August 2026 | Hostetter Shane | Chief Financial Officer | Open-market purchase | +3,350 | $14.94 | 102,698 | Form 4 |
| 1 August 2026 | Familiar Calderon Gerardo | See Remarks | Shares withheld for tax | −943 | $16.61 | 58,499 | Form 4 |
| 1 August 2026 | Wellman Kristine M | SVP, GC & Corp. Secretary | Shares withheld for tax | −391 | $16.61 | 74,419 | Form 4 |
| 1 August 2026 | Dignam Denise | Chief Executive Officer | Shares withheld for tax | −477 | $16.61 | 337,493 | Form 4 |
| 1 August 2026 | Martinko Joseph T. | See Remarks | Shares withheld for tax | −663 | $16.61 | 54,819 | Form 4 |
| 6 May 2026 | Brokaw George R | Director | Grant or award | +7,182 | — | 21,643 | Form 4 |
| 6 May 2026 | Kava Joseph Daniel | Director | Grant or award | +7,182 | — | 24,603 | Form 4 |
| 6 May 2026 | Keohane Sean D | Director | Grant or award | +7,182 | — | 72,555 | Form 4 |
| 6 May 2026 | Satterthwaite Livingston | Director | Grant or award | +7,182 | — | 30,808 | Form 4 |
| 6 May 2026 | Kane Erin N | Director | Grant or award | +7,182 | — | 74,063 | Form 4 |
| 6 May 2026 | Mather Courtney | Director | Grant or award | +7,182 | — | 21,643 | Form 4 |
| 6 May 2026 | Cowan Alister | Director | Grant or award | +7,182 | — | 43,881 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Chemours page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.